An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Kaspers GJL, Niewerth D, Wilhelm BAJ, van Houtem PScholte-, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathot RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Roessig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich P-S, Simon P, von Stackelberg A, Zwaan CMichel |
| Journal | BRITISH JOURNAL OF HAEMATOLOGY |
| Volume | 181 |
| Pagination | 523-527 |
| Date Published | MAY |
| Type of Article | Article |
| ISSN | 0007-1048 |
| Mots-clés | acute leukaemia, bortezomib, childhood leukaemia, pharmacokinetics, proteasome inhibitor |
| Résumé | This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3mg/m(2)/dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid. |
| DOI | 10.1111/bjh.15233 |